KA LAWELAWE HOʻOKOMO ʻANA I KA COAGULATION DIAGNOSIS
NOI NO NĀ REAGENTS ANALYZER
He ʻepekema a he hana noʻeau hoʻi ka nānā pono ʻana i nā lāʻau heparin, a pili pono ia i ka holomua a i ʻole ka hāʻule ʻana o ka lāʻau anticoagulant.
Hoʻohana pinepine ʻia nā lāʻau Heparin i nā anticoagulants no ka pale ʻana a me ka mālama ʻana i nā maʻi thromboembolic a hoʻohana nui ʻia i nā ʻano lapaʻau he nui.
Eia nō naʻe, ʻo ke ʻano o ka hoʻohana pono ʻana a me ka nānā pono ʻana i kēia mau lāʻau lapaʻau e hōʻoia i ka palekana a me ka pono o ka lāʻau lapaʻau ka mea i manaʻo nui ʻia e nā kauka.
ʻO ka mea i hoʻokuʻu ʻia nei "Ka ʻaelike loea ma ka nānā ʻana i nā lāʻau lapaʻau Heparin"ua kūkākūkā piha i nā hōʻailona, ka nui, ka nānā ʻana a me nā ʻano ʻē aʻe o nā lāʻau heparin, ua wehewehe pono i nā ʻano noi lapaʻau o nā ʻōkuhi hale hana e like me ka hana anti-Xa.
E hōʻuluʻulu kēia ʻatikala i nā kumu nui o kēia ʻaelike e kōkua i nā limahana lapaʻau e hoʻopili maikaʻi iā ia i ka hana maoli.
1-Koho ʻana o nā ʻōkuhi nānā ʻana i ka hale hana
Hoʻomaopopo ka manaʻo like i nā mea maʻamau e pono e nānā ʻia ma mua a i ka wā o ka hoʻohana ʻana i nā lāʻau heparin e komo pū me ka palena ʻole i ka hemodynamics, ka hana renal, ka hemoglobin, ka helu platelet a me ke koko huna i loko o ka ʻōpala.
2-Nā kiko koʻikoʻi no ka nānā ʻana i nā lāʻau heparin like ʻole
(1) Heparin ʻoki ʻole ʻia (UFH)
Pono e nānā ʻia ka nui o ka UFH therapeutic a hoʻoponopono ʻia ka nui e like me ka hana anticoagulant.
Hoʻohana ʻia ka nānā ʻana iā ACT no ka hoʻohana ʻana i nā mahele kiʻekiʻe (e like me ka wā o ka PCI a me ke kahe ʻana o ka extracorporeal [CPB]).
I nā kūlana ʻē aʻe (e like me ka mālama ʻana i ka ACS a i ʻole VTE), hiki ke koho ʻia ka APTT i hoʻoponopono ʻia no ka hana anti-Xa a i ʻole ka hana anti-Xa.
(2) Heparin kaumaha molekala haʻahaʻa (LMWH)
Wahi a nā ʻano pharmacokinetic o LMWH, ʻaʻole koi ʻia ka nānā mau ʻana i ka hana anti-Xa.
Eia nō naʻe, pono nā mea maʻi me ke kaumaha o ke kino kiʻekiʻe a haʻahaʻa paha, hāpai, a i ʻole ka lawa ʻole o ka renal e hana i kahi loiloi palekana a i ʻole ka hoʻoponopono ʻana i ka lāʻau ma muli o ka hana anti-Xa.
(3) Ka nānā ʻana i ka sodium Fondaparinux
ʻAʻole pono nā maʻi e hoʻohana ana i nā dosis pale a therapeutic paha o ka fondaparinux sodium i ka nānā mau ʻana i ka hana anti-Xa, akā ua ʻōlelo ʻia ka nānā ʻana i ka hana anti-Xa i nā maʻi momona me ka lawa ʻole o ka renal.
3- Ke kū'ē ʻana iā Heparin a me ka mālama ʻana iā HIT
Ke kānalua ʻia ka hemahema o ka antithrombin (AT) a i ʻole ke kūʻē ʻana i ka heparin, ua ʻōlelo ʻia e hoʻāʻo i nā pae hana AT e kāpae i ka hemahema o AT a alakaʻi i ka lāʻau hoʻololi e pono ai.
Manaʻo ʻia e hoʻohana i kahi hoʻāʻo substrate chromogenic e pili ana iā IIa (loaʻa ka bovine thrombin) a i ʻole Xa no ka hana AT.
No nā poʻe maʻi i manaʻo ʻia he thrombocytopenia i hoʻokomo ʻia e ka heparin (HIT), ʻaʻole ʻōlelo ʻia ka hoʻāʻo ʻana i ka antibody HIT no nā poʻe maʻi i hōʻike ʻia e UFH me ka haʻahaʻa o ka hiki ke loaʻa iā HIT (≤3 mau helu) ma muli o ka helu 4T.
No nā poʻe maʻi me kahi likelika lapaʻau waena a kiʻekiʻe paha o HIT (4-8 mau helu), ua ʻōlelo ʻia ka hoʻāʻo ʻana i ka antibody HIT.
Manaʻo ʻia kahi paepae kiʻekiʻe aʻe no ka hoʻāʻo ʻana i ka antibody i hui pū ʻia, ʻoiai ua manaʻo ʻia kahi paepae haʻahaʻa no ka hoʻāʻo ʻana i ka antibody IgG-kikoʻī.
4- Hoʻokele pilikia koko a me ka hoʻōla hoʻohuli
I ka hanana ʻana o ke kahe koko nui e pili ana i ka heparin, pono e hoʻōki koke i nā lāʻau antithrombotic, a pono e mālama koke ʻia ka hemostasis a me ke kūpaʻa hemodynamic i ka hikiwawe loa.
Manaʻo ʻia ʻo Protamine ma ke ʻano he lāʻau lapaʻau laina mua no ka hoʻopau ʻana i ka heparin.
Pono e helu ʻia ka nui o ka protamine ma muli o ka lōʻihi o ka hoʻohana ʻana i ka heparin.
ʻOiai ʻaʻohe ʻano nānā kikoʻī no ka protamine, hiki ke hana ʻia ka loiloi lapaʻau o ka hopena hoʻohuli o ka protamine ma ka nānā ʻana i ke kūlana kahe koko o ka mea maʻi a me nā loli i ka APTT.
ʻAʻohe antidote kikoʻī no ka fondaparinux sodium; hiki ke hoʻohuli ʻia kona hopena anticoagulant me ka hoʻohana ʻana i ka FFP, PCC, rFVIIa, a me ka hoʻololi plasma.
Hāʻawi kēia ʻaelike i nā kaʻina hana nānā kikoʻī a me nā waiwai i manaʻo ʻia, e kōkua ana iā mākou e hana i nā hoʻoholo pololei i ka hana lapaʻau.
He pahi kaua ʻoi pālua ka lāʻau anticoagulant: hiki i ka hoʻohana kūpono ke pale a mālama i nā maʻi thrombosis, akā hiki i ka hoʻohana pono ʻole ke hoʻonui i ka pilikia o ke kahe ʻana o ke koko.
Ke lana nei ko mākou manaʻo e kōkua ka wehewehe ʻana i kēia manaʻo like iā ʻoe e lilo i ʻoi aku ka maikaʻi ma ka hana lapaʻau a hāʻawi i ka lāʻau anticoagulant palekana a ʻoi aku ka maikaʻi no kāu mau maʻi.
Ua komo nui ʻo Beijing Succeeder Technology Inc. (code stock: 688338) i ke kahua o ka ʻike ʻana i ka coagulation mai kona hoʻokumu ʻia ʻana i ka makahiki 2003, a ua kūpaʻa ʻo ia e lilo i alakaʻi ma kēia kahua. Me ke keʻena nui ma Beijing, he hui R&D, hana a kūʻai aku ikaika ka hui, e kālele ana i ka hana hou a me ka hoʻohana ʻana i ka ʻenehana ʻike thrombosis a me hemostasis.
Me kona ikaika loea koʻikoʻi, ua lanakila ʻo Succeeder i 45 mau palapala sila i ʻae ʻia, me 14 mau palapala sila i hana ʻia, 16 mau palapala sila hoʻohālike pono a me 15 mau palapala sila hoʻolālā.
Loaʻa i ka ʻoihana he 32 mau palapala hoʻopaʻa inoa huahana hāmeʻa lapaʻau Papa II, 3 mau palapala hoʻopaʻa waihona Papa I, a me ka palapala hōʻoia EU CE no 14 mau huahana, a ua hala i ka palapala hōʻoia ʻōnaehana hoʻokele maikaʻi ISO 13485 e hōʻoia i ka maikaʻi a me ke kūpaʻa o ka maikaʻi o ka huahana.
ʻAʻole wale ʻo Succeeder kahi ʻoihana koʻikoʻi o ka Beijing Biomedicine Industry Leapfrog Development Project (G20), akā ua pae maikaʻi ʻia hoʻi ma ka Science and Technology Innovation Board i ka makahiki 2020, e hoʻokō ana i ka hoʻomohala leapfrog o ka ʻoihana.
I kēia manawa, ua kūkulu ka ʻoihana i kahi pūnaewele kūʻai aku ma ka ʻāina holoʻokoʻa e uhi ana i nā haneli o nā ʻelele a me nā keʻena.
Ua kūʻai maikaʻi ʻia kāna huahana ma ka hapa nui o nā wahi o ka ʻāina.
Ke hoʻonui ikaika nei ia i nā mākeke o nā ʻāina ʻē a ke hoʻomaikaʻi mau nei i kona hoʻokūkū honua.
Kāleka ʻoihana
WeChat Kina